|
|
|
|
| LEADER |
03292nmm a2200277 u 4500 |
| 001 |
EB000285972 |
| 003 |
EBX01000000000000000050209 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
090727 ||| eng |
| 020 |
|
|
|a 9781592596584
|
| 050 |
|
4 |
|a RC633-647
|
| 100 |
1 |
|
|a Mousa, Shaker A.
|e [editor]
|
| 245 |
0 |
0 |
|a Anticoagulants, Antiplatelets, and Thrombolytics
|h Elektronische Ressource
|c edited by Shaker A. Mousa
|
| 250 |
|
|
|a 1st ed. 2004
|
| 260 |
|
|
|a Totowa, NJ
|b Humana Press
|c 2004, 2004
|
| 300 |
|
|
|a X, 310 p
|b online resource
|
| 505 |
0 |
|
|a Highlights of Latest Advances in Antithrombotics -- Antiplatelet, Anticoagulant, and Thrombolytic Drug Interactions -- Evaluation of Platelet Antagonists in In Vitro Flow Models of Thrombosis -- Heparin and Low Molecular Weight Heparin in Thrombosis, Cancer, and Inflammatory Diseases -- Are Low Molecular Weight Heparins the Same? -- Antithrombotic Drugs for the Treatment of Heparin-Induced Thrombocytopenia -- Laboratory Methods for Heparin-Induced Thrombocytopenia -- Factor Xa Inhibitors -- Tissue Factor/VIIa in Thrombosis and Cancer -- Tissue Factor Pathway Inhibitor in Thrombosis and Beyond -- Cell Adhesion Molecules -- Development and Applications of Animal Models of Thrombosis -- A Survey of Venous Thrombosis Models -- Arixtra® (Fondaparinux Sodium) -- Oral Thrombin Inhibitor Ximelagatran -- Pharmacogenomics and Coagulation Disorders -- Guidelines for Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism
|
| 653 |
|
|
|a Hematology
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SPRPROT
|a Springer Protocols Archive 1981-2004
|
| 490 |
0 |
|
|a Methods in Molecular Medicine
|
| 024 |
8 |
|
|a 10.1385/1592596584
|
| 856 |
4 |
0 |
|u https://doi.org/10.1385/1592596584?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.15
|
| 520 |
|
|
|a During the past decade, remarkable progress has been made in the development of new drugs to treat thrombotic and cardiovascular diseases, the number one cause of mortality worldwide. In Anticoagulants, Antiplatelets, and Thrombolytics, leading experts with established records of discovery and invention highlight the latest developments in antithrombotics and provide experimental methods for the discovery of new and improved anticoagulants. Among the cutting-edge developments reviewed are the novel usage of low molecular weight heparins, such antithrombin agents as hirudin, and such antiplatelet drugs as the GPIIb/IIIa inhibitors and ADP-receptor antagonists. Additional innovations discussed include aspirin and clopidogrel, the expanded use of polytherapeutic approaches, antiproteases (factors IIa, Xa, and VIIa), tissue-factor targeting, platelet-receptor targeting, and antithrombin III modulation. The authors also define the clinically relevant in vitro and in vivo models of thrombosis and hemostasis that led to these advances and that will surely aid in the discovery of the next generation of antithrombotics. Up-to-date and forward-looking, Anticoagulants, Antiplatelets, and Thrombolytics illuminates the latest developments in the field of thrombosis and provides both basic and clinical investigators a broad array of successful experimental methods for the discovery and development of novel drugs to treat thrombotic and cardiovascular diseases
|